US Stock MarketDetailed Quotes

NGENF NERVGEN PHARMA CORP

Watchlist
  • 1.610
  • +0.020+1.26%
Close Mar 28 16:00 ET
95.81MMarket Cap-6625P/E (TTM)

About NERVGEN PHARMA CORP Company

NervGen Pharma Corp. operates as a regenerative medicine company engaged in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University in Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was founded by Punnett Harold and William Joseph Radvak on January 19, 2017 and is headquartered in Vancouver, Canada.

Company Profile

SymbolNGENF
Company NameNERVGEN PHARMA CORP
Founded2017
CEOMr. Michael Kelly
MarketPink Market
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address2955 Virtual Way,Suite 480
CityVancouver
ProvinceBritish Columbia
CountryCanada
Zip CodeV5M 4X6
Phone1-778-731-1711

Company Executives

  • Name
  • Position
  • Salary
  • Michael Kelly
  • Director, President and Chief Executive Officer
  • --
  • William J. Adams
  • Chief Financial Officer and Corporate Secretary
  • --
  • Dr. Daniel D. Mikol, M.D.
  • Chief Medical Officer
  • --
  • William Joseph Radvak
  • Chairman of the Board
  • --
  • Dr. Adam H. Rogers
  • Director
  • --
  • Brian Eric Bayley
  • Independent Director
  • --
  • Dr. Randall E. Kaye,M.D.
  • Independent Director
  • --
  • Dr. Harold Punnett
  • Independent Director
  • --
  • John Craig Thompson
  • Independent Director
  • --
  • Glenn A. Ives
  • Independent Director
  • --
  • Krista McKerracher
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg